Back to top
more

Merit Medical Systems (MMSI)

(Real Time Quote from BATS)

$83.43 USD

83.43
9,938

+0.10 (0.12%)

Updated Jun 6, 2024 10:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 248)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain Luminex (LMNX) Stock for Now

by Zacks Equity Research

Investor confidence is high on Luminex (LMNX) stock, thanks to solid prospects.

Here's Why You Should Avoid Betting on Integer Holdings Now

by Zacks Equity Research

Stiff competition in the MedTech space and weak segmental and operational performance weighs on Integer Holdings (ITGR).

Cerner Inks Deal to Simplify Advance Care Planning Procedure

by Zacks Equity Research

Cerner's (CERN) partners with Vynca to simplify advance care planning process, thereby enabling patients and clinicians to discuss and make critical end-of-life decisions.

Zacks Value Trader Highlights: NortonLifeLock, Advance Auto Parts, Aecom, Green Dot and Merit Medical

by Zacks Equity Research

Zacks Value Trader Highlights: NortonLifeLock, Advance Auto Parts, Aecom, Green Dot and Merit Medical

Sriparna Ghosal headshot

3 Great MedTech Stocks to Pick Amid the Coronavirus Crisis

by Sriparna Ghosal

Backed by projections of robust earnings growth rates, there are a few MedTech stocks which are ideal for long-term bet.

Tracey Ryniec headshot

Should Value Investors Buy SPACs?

by Tracey Ryniec

Value hedge fund managers are launching SPACs in 2020 as value investors struggle to keep up with the return on growth stocks.

Baxter's Clinimix and Clinimix E Injections Receive FDA Nod

by Zacks Equity Research

Baxter's (BAX) Clinimix and Clinimix E with Higher Protein Injection received FDA approval, which will help clinicians to improve care for critically ill patients.

Veeva CRM to Help Medis Deliver Customized Experience to HCPs

by Zacks Equity Research

Veeva Systems' (VEEV) CRM will be lending Medis teams a flexible solution that adapts to the unique go-to market strategies of every customer.

Here's Why You Should Add NextGen Stock to Your Portfolio Now

by Zacks Equity Research

Investor optimism is high on NextGen (NXGN) stock, thanks to solid prospects.

AngioDynamics Unveils Auryon Atherectomy System for PAD

by Zacks Equity Research

AngioDynamics' (ANGO) Auryon Atherectomy System leverages breakthrough technology to deliver treatment of PAD lesions and occlusions.

Accuray's Radixact With Synchrony Used in Japan Hospitals

by Zacks Equity Research

The integration of Synchrony to Accuray's (ARAY) Radixact System will ensure that the hospital teams can efficiently deliver precise radiation doses to tumors.

DexCom Introduces Registry to Monitor Outcomes of G6 System

by Zacks Equity Research

DexCom (DXCM) sets up registry to track outcomes of patients and healthcare professionals using CGM in hospitals.

Here's Why You Should Retain Avanos Medical Stock for Now

by Zacks Equity Research

Investor confidence is high on Avanos Medical (AVNS), thanks to solid prospects.

Here's Why You Should Add Surmodics to Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on Surmodics (SRDX) stock, thanks to solid prospects.

Here's Why You Should Retain Allscripts (MDRX) Stock for Now

by Zacks Equity Research

Investor confidence is high on Allscripts (MDRX) stock, thanks to solid prospects.

Here's Why You Should Add DaVita (DVA) to Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on DaVita (DVA) stock, thanks to solid prospects.

Here's Why You Should Hold on to CONMED (CNMD) Stock for Now

by Zacks Equity Research

Investor confidence is high on CONMED (CNMD) stock, thanks to solid prospects.

OPKO Health's BioReference Laboratories Introduces NGS Assay

by Zacks Equity Research

OPKO Health's (OPK) OnkoSight Advanced is a NGS assay that facilitates revolutionary DNA mutational profiling of tumor samples.

Baxter (BAX) Attains FDA De Novo Authorization for Theranova

by Zacks Equity Research

Baxter's (BAX) expanded HDx therapy delivered by Theranova becomes accessible for patients with kidney failure in the United States.

Masimo's (MASI) O3 Regional Oximetry Attains FDA Approval

by Zacks Equity Research

Masimo's (MASI) O3 Regional Oximetry's FDA clearance can help clinicians offer quick and accurate care

Here's Why You Should Retain Inogen in Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on Inogen (INGN) stock, thanks to solid prospects

Why Is Merit Medical (MMSI) Up 7.1% Since Last Earnings Report?

by Zacks Equity Research

Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Smith+Nephew Unveils Digital Platform to Boost Patient Care

by Zacks Equity Research

With the help of the care management platform, Smith+Nephew (SNN) aims to help clinicians reduce the patient's post-acute recovery time.

Here's Why You Should Retain Luminex (LMNX) Stock for Now

by Zacks Equity Research

Investor confidence is high on Luminex (LMNX) stock, thanks to solid prospects.

Here's Why You Should Retain HMS Holdings in Your Portfolio

by Zacks Equity Research

Investor confidence is high on HMS Holdings (HMSY) , thanks to solid prospects.